

Asthma Indicators for LHIN 8: Central

Indicator	Asthma Indicators for LHIN 8: Central																						
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017*	2018*
1. PFT used for diagnosis (% of incident asthma) [†]	52.96	54.64	51.45	48.78	46.87	44.18	43.23	41.26	43.11	44.58	45.91	46.50	45.81	46.36	46.66	47.05	47.20	48.35	50.89	52.03	52.78	52.10	53.73
2. PFT used for monitoring (% of prevalent asthma) [†]	17.34	15.59	15.19	13.35	12.02	11.11	9.54	8.76	8.15	8.09	8.11	7.87	7.26	7.47	7.43	7.11	6.84	6.41	6.28	6.48	6.57	6.61	6.52
3. ≥1 ICS prescription (% of prevalent asthma) [‡]	55.45	53.83	52.34	50.60	50.41	49.89	48.13	46.15	46.16	46.20	44.84	45.62	45.03	44.85	44.99	47.42	46.97	47.27	46.63	47.05	46.08	43.22	40.43
4. ≥1 β2-agonist prescription (% of prevalent asthma) [‡]	56.42	53.64	51.55	49.57	48.96	46.65	43.35	40.17	38.92	38.83	36.34	35.69	33.57	32.27	32.19	32.60	31.00	30.90	28.00	20.74	20.75	19.57	20.23
5. ≥1 asthma ED visit (% of prevalent asthma)	4.11	3.55	3.22	2.94	2.81	2.48	2.35	1.53	1.40	1.45	1.40	1.22	1.07	0.99	0.95	0.89	0.81	0.82	0.77	0.82	0.74	0.73	0.74
6. ≥1 asthma physician office visit (% of prevalent asthma)	37.75	34.15	31.52	30.08	27.89	27.29	24.37	22.56	21.64	21.22	20.78	20.16	18.55	18.00	18.06	16.55	15.46	15.24	14.72	14.90	14.56	14.10	14.09
7. β2-agonist use (% of prevalent asthma) [‡]																							
0	43.58	46.36	48.45	50.43	51.04	53.35	56.65	59.83	61.08	61.17	63.66	64.31	66.43	67.73	67.81	67.40	69.00	69.10	72.00	79.26	79.25	80.43	79.77
1-2	20.30	20.10	19.94	19.52	20.07	19.48	18.15	17.29	17.56	18.33	16.92	16.83	16.40	15.77	16.26	16.34	16.00	16.46	15.13	10.92	11.10	10.29	10.88
≥3	36.12	33.54	31.61	30.05	28.88	27.16	25.21	22.88	21.36	20.51	19.42	18.86	17.17	16.50	15.93	16.26	14.99	14.44	12.87	9.82	9.65	9.29	9.35

*Reporting period is from April 1996 to March 2019. Data for 2017 and 2018 may be incomplete due to the 2-year algorithm to identify asthma, and numbers are subject to change.

PFT = pulmonary function test; ICS = inhaled corticosteroid; ED = emergency department; ODB = Ontario Drug Benefit; OHIP = Ontario Health Insurance Plan; LHIN = Local Health Integration Network; HSU = health services use

[†]PFT data refers to individuals aged 7-99 years in the asthma prevalent population.

[‡]Drug use data refers to individuals aged 66-99 years with complete year ODB coverage in the asthma prevalent population.

Technical notes:

^aOHIP data was up to December 2019 when the tables were created.

^bFor asthma incidence from July 2017 to March 2019, PFT data for 2.5-year post asthma incidence are not complete as latest data were available up to December 2019 when the tables were created.

^cIndividuals with missing LHIN, rurality, or without OHIP coverage were excluded.

^dAsthma incidence of the year were excluded from this table, except for indicator 1.

^eIndex date is defined as the first service date of asthma HSU, or any HSU if there was no asthma HSU, or April 1 if there was no HSU during the year.

Asthma indicators - detailed description:

1. Percent of asthma incidence aged 7 years and above with a PFT in one year prior to or 2.5 years after incidence date^{a-c}
2. Percent of asthma prevalence aged 7 years and above with a PFT in one year prior to the index date^{a,c-e}
3. Percent of asthma prevalence 66 years and above with at least one prescription of ICS in one year prior to the index date^{c-e}
4. Percent of asthma prevalence aged 66 years and above with at least one prescription of β2-agonist in one year prior to the index date^{c-e}
5. Percent of asthma prevalence with at least one ED visit in one year prior to the index date^{c-e}
6. Percent of asthma prevalence with at least one physician office visit in one year prior to the index date^{c-e}
7. Distribution of the three categories of β2-agonist use for asthma prevalence aged 66 years and above^{c,d}

Source: This table uses statistics reported by the Ontario Asthma Surveillance Information System (OASIS) and data provided by ICES, Ontario.